Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.41 |
| ▸ | CCKAR | P32238 | 3/20 | 0.40 |
| ▸ | CCKBR | P32239 | 3/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15487826 | 0.87 | AADAT (0.68) | AADATALDH1A1RIPK1 | |
| SCHEMBL14136608 | 0.83 | AADAT (0.69) | AADATALDH1A1RIPK1 | |
| SCHEMBL15493879 | 0.82 | AADAT (0.71) | AADATKMT2AL3MBTL1ALDH1A1RIPK1 | |
| SCHEMBL14124977 | 0.82 | AADAT (0.47) | AADATKMT2AL3MBTL1SCN9AALDH1A1 | |
| SCHEMBL14136962 | 0.79 | AADAT (0.64) | AADATKMT2AL3MBTL1SCN9ANPY1R | |
| SCHEMBL14053143 | 0.76 | AADAT (0.62) | AADATALDH1A1RIPK1 | |
| SCHEMBL9912538 | 0.75 | AADAT (1.00) | AADAT | |
| SCHEMBL9912518 | 0.74 | AADAT (0.60) | AADATKMT2AL3MBTL1SCN9ANPY1R | |
| SCHEMBL29048164 | 0.74 | SMN1; SMN2 (0.57) | KMT2AL3MBTL1SCN9ANPY1RALDH1A1 | |
| SCHEMBL6763198 | 0.74 | AADAT (0.49) | AADATSCN9ANPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073143-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057938-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | AADAT 2414/4885KMT2A 215/4885L3MBTL1 8/4885 |
| US-20120302599-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | AADAT 2414/4885KMT2A 215/4885L3MBTL1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.